Cat. No. 3370
Chemical Name: (±)-(3R*,4S*)-2-Oxo-4-phenyl-3-pyrol
Biological ActivityPotent and selective protease-activated receptor 2 (PAR2) agonist (pEC50 = 7.5). Displays no activity at other PAR subtypes and exhibits no significant activity at over 30 other receptors implicated in nociception and inflammation. Stimulates PI hydrolysis, Ca2+ mobilization and cellular proliferation in vitro (pEC50 values are 6.9, 7.0 and 7.5 respectively).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Gardell et al (2008) Identification and characterization of novel small-molecule protease-activated receptor 2 agonists. J.Pharmacol.Exp.Ther. 327 799. PMID: 18768780.
Seitzberg et al (2008) Discovery of potent and selective small-molecule PAR-2 agonists. J.Med.Chem. 51 5490. PMID: 18720984.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses AC 264613 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: AC 264613, supplier, Potent, selective, PAR2, agonists, receptors, protease-activated, proteinase-activated, AC264613, Tocris Bioscience, Protease-Activated Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Non-peptide apelin receptor agonistBML 111
FPR2 (lipoxin A4 receptor) agonistAmylin (rat)
Potent endogenous peptide agonist for amylin, calcitonin, CGRP and adrenomedullin receptorsCalcitonin (human)
Endogenous calcitonin receptor agonist; inhibits bone resorptionSpexin
Potent GAL2/3 agonist; exhibits anxiolytic effects in vivoMM 54
Potent apelin receptor antagonistMSG 606
Potent human MC1 receptor antagonist; also MC3 and MC5 partial agonist
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.